INO. 10/10/12 Inovio Pharmaceuticals' Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells -- Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection -- On-going phase II efficacy study will determine vaccine's ability to reverse disease progression to cervical cancer http://ih.advfn.com/p.php?pid=nmona&article=54469478
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.